Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Geriatric cognitive evaluation and prostate cancer

SIOG 2017

9 - 11 Nov 2017

Published: 15 Nov 2017

Views: 2589

Rating:

Save

Prof Nicolas Mottet - University Hospital of Saint-Etienne, St. Etienne, France

Prof Mottet speaks to ecancer at SIOG 2017 in Warsaw about assessing cognitive function of geriatric cancer patients.

He highlights the updates regarding to prostate cancer and ADT.

For more on cognitive function in geriatric cancer patients, watch Dr Carla Ripamonti discuss it here.

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of...

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

Assessment of QoL results and correlation with survival outcomes in phase III...

Dr Alberto Servetto - University of Naples Federico II, Naples, Italy

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC ( Dr Alberto Servetto - University of Naples Federico II, Naples, Italy )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible...

Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York...

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

More from ecancer